FIELD: medicine.
SUBSTANCE: invention refers to using progestogen specified in a group consisting of 17HPC, P4 and MPA as a component of a pharmaceutical composition for glucocorticoid sensitisation of peripheral mononuclear blood cells (PBMC) taken from an individual suffering glucocorticoid insensibility, glucocorticoid hypersensibility or reversed glucocorticoid insensibility, with the individual suffering no menstrual cycle related recurrence, whereas the glucocorticoid insensibility related conditions include immunoinflammatory disorders/diseases treated by a steroid therapy, which has fail to control the disease or appears ineffective, or intolerant, or corticosteroid-dependent, or any combination thereof.
EFFECT: method makes it possible to improve the therapeutic effect in glucocorticoid insensibility.
12 dwg, 4 tbl, 8 ex
Authors
Dates
2016-02-20—Published
2011-02-07—Filed